Encorafenib, sold under the brand name Braftovi, is an anti-cancer medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor [4] that targets …

2016年1月28日 · Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clinical trials. However, the underlying mechanism remains to be elucidated. …

Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E (EC50 =4 nM).

2012年4月15日 · LGX818 is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E. In the A375 (BRAF V600E) human …

2022年11月24日 · Encorafenib (LGX818, trade name Braftovi), a novel BRAF inhibitor, has been approved for the treatment of melanoma and colorectal cancer. In the present work, we …

2017年9月15日 · Results: Preclinical data demonstrated that encorafenib inhibited BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of …

Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine / threonine enzyme in the RAF/mitogen …

LGX818按1 mg/kg低剂量处理免疫受损小鼠和大鼠，作用于多种BRAF突变的人类移植瘤模型，诱导肿瘤消退。 与体外数据相一致，LGX818对BRAF野生型肿瘤是无作用活性的，即使每天两 …

2014年9月1日 · Encorafenib, a potent and selective oral BRAF inhibitor, showed signs of efficacy in pts with BRAF-mutant advanced melanoma in a phase 1 dose-escalation study. Here we …

profile and efficacy of LGX818/MEK162 and LGX818/MEK162/LEE011 combinations in patients with solid tumors harboring a BRAF V600 mutation. In addition, the CSR also report the …